Quest Diagnostics Incorporated benefits from steady demand for routine testing and growth opportunities in dialysis and advanced diagnostics. The company's acquisition strategy currently supports its cash flow, though risks remain if execution or reimbursement falter, potentially leading to goodwill write-downs. Despite near-term uncertainties with Medicare, Quest Diagnostics' valuation makes it a speculative buy for investors seeking growth in healthcare diagnostics.
Quest Diagnostics Inc trades at USD 234.90 on Pluang as of Sep 23, 2026 20:02 WIB, showing a slight 0.02% increase in one day. The stock holds a market cap of $25.91 billion and a dividend yield of 1.47%. Pluang investors currently show full buying interest with 100% buy orders and no sell activity, reflecting steady confidence in the healthcare diagnostics sector.
Quest Diagnostics announced it will release its third quarter 2026 financial results on October 22, 2026, before the market opens. The company will hold a conference call at 8:30 a.m. Eastern Time to discuss the results, accessible via phone and webc...
A large study of over 193,000 U.S. patients found that nearly 30% of those with Lyme disease antibodies also had antibodies to other tick-borne pathogens like Babesia and Anaplasma. This co-exposure is especially common in the Northeast and highlight...
